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T-cell growth factor: Complete nucleotide sequence and
organization of the gene in normal and malignant cells
(gene structure/human DNA library screening/lymphokines/interleukin 2)
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ROBERT L. WISKOCILt, AND GERALD R. CRABTREE*
*Hematopathology Section, Building 10, Room 2N-113, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20205; tImmunology Program,
Dartmouth Medical School, Norris Cotton Cancer Center, Hanover, NH 03756; and tHoward Hughes Medical Institute, University of California, San
Francisco, CA 94143
Communicated by David W. Talmage, November 14, 1983
ABSTRACT Using a cloned cDNA copy of T-cell growth
factor (TCGF) mRNA from the Jurkat leukemic T-cell line, we
have isolated three overlapping TCGF genomic clones from a
human DNA library. The entire TCGF gene is contained with-
in two adjacent EcoRI fragments spanning about 8 kilobases.
The complete nucleic acid sequence was determined. The gene
is divided into four exons. The 5' untranslated region and the
first 49 amino acids of the protein, 20 of which constitute a
signal polypeptide and are not present in the secreted protein,
are encoded by the first exon. Exons 2 and 3, separated from
each other by a long intervening sequence, contain coding in-
formation for the next 20 and 48 amino acids, respectively.
The remaining 36 amino acids and the 3' untranslated region
are contained in the fourth exon. A promoter sequence T-A-T-
A-A-A is present 77 base pairs (bp) upstream from the transla-
tion initiation site, and a CAT homology region occurs 104 bp
upstream from the initiation site. A putative site for initiation
of mRNA transcription was identified 53 bp 5' of the transla-
tion initiation codon. The organization of the gene was shown
by Southern blot analysis to be identical in normal peripheral
blood lymphocytes and in a variety of malignant lymphoid cell
types. Restriction analysis of these cellular DNAs produced re-
sults exactly as predicted by the map for the cloned genomic
TCGF, indicating that there is only a single copy of the human
TCGF gene.
T-cell growth factor (TCGF), also known as interleukin 2
(IL-2), is a protein produced by T lymphocytes that is capa-
ble of initiating and maintaining long term in vitro growth of
activated T cells (1). TCGF was first shown to be released
into media from lectin-stimulated human peripheral blood
and bone marrow T-cell cultures, but it has since been
shown to be present in other mammalian systems (1, 2). Hu-
man TCGF has been purified to homogeneity and has a mo-
lecular weight of about 15,000 (3-5). Taniguchi et al. (6) re-
cently reported the first cloning and nucleotide sequence of
the cDNA coding for TCGF from the human Jurkat leukemic
T-cell line. The cDNA codes for a protein of 153 amino ac-
ids, the first 20 of which appear to constitute a signal poly-
peptide and do not appear in the secreted protein (6).
Because it plays a key regulatory role in mediating T-cell
proliferation, TCGF has been suggested as a possible treat-
ment for immunodeficiency syndromes as well as a means of
obtaining large numbers of tumor-specific cytotoxic cells for
immunotherapy of malignancy. Mitogens such as phytohe-
magglutinin and concanavalin A induce TCGF production in
human T lymphocytes (3, 7). Phorbol myristic acetate by it-
self does not induce TCGF production, but it greatly en-
hances the induction by mitogen (3, 7). An understanding of
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the processes involved in the mitogenic stimulation ofTCGF
activity would surely contribute to our overall understanding
of T-cell differentiation. To investigate the molecular mecha-
nisms through which mitogens induce TCGF we have cloned
the gene from a human DNA library. We report the complete
nucleotide sequence of the gene for TCGF and its organiza-
tion in normal and malignant cells.
MATERIALS AND METHODS
Preparation and Screening of a cDNA Library for TCGF.
Polyadenylylated TCGF RNA was prepared (8) from the hu-
man Jurkat leukemic T-cell line after stimulating the cells for
6 hr with phytohemagglutinin (1.5 ,tg/ml) and phorbol myris-
tic acetate (50 ng/ml). The RNA was fractionated on a su-
crose density gradient and TCGF mRNA activity was moni-
tored by translation in a rabbit reticulocyte lysate and immu-
noprecipitation of TCGF using a monoclonal antibody to
TCGF (9). Double-stranded cDNA was prepared and the
cDNA was inserted into pBR322 at the Pst I site using the
standard G-C tailing method (10). The library was screened
for TCGF sequences after transformation into Escherichia
coli HB101 using an 18-mer synthetic oligonucleotide probe
(G-C-A-C-C-T-A-C-T-T-C-A-A-G-T-T-C-T) from positions
108-125 of the reported sequence of TCGF cDNA (6). Colo-
nies grown overnight on nitrocellulose filters overlying LB
agar containing tetracycline (20 ,g/ml) were lysed as de-
scribed by Thayer (11). Filters were hybridized overnight at
50°C with the probe end-labeled with [y-32P]ATP in 6x NET
(lx NET is 0.15 NaCl/0.015 M Tris-HCl, pH 7.5/0.001 M
EDTA), 5x Denhardt's solution (lx Denhardt's solution is
0.02% bovine serum albumin/0.02% Ficoll/0.02% polyvinyl-
pyrrolidone)/0.5% Nonidet P-40/10% (vol/vol) dextran sul-
fate/salmon sperm DNA (250 ,ug/ml). The filters were
washed at 0°C with four changes each in 6x standard saline
citrate (lx standard saline citrate is 0.15 M NaCl/0.015 M
sodium citrate, pH 7.2) for a total of 20 min, then at 50°C for
1 min in 6x standard saline citrate.
Isolation and Mapping of the Gene. Approximately 1 x 106
plaques from three human genomic libraries were screened
by the Benton-Davis procedure (12) using the 32P-labeled
cDNA probe for TCGF. DNA was prepared from plaque-
purified clones according to Maniatis et al. (13). Restriction
endonuclease digestions were carried out on the resulting
samples according to the manufacturers' instructions and
samples were analyzed on 0.8-1.2% agarose gels. The struc-
tural organization of the TCGF gene in normal peripheral
blood lymphocytes and various malignant lymphoid cell
types was examined by hybridization of cellular DNA to 32p
labeled TCGF cDNA using the standard Southern blot pro-
cedure (14).
Abbreviations: TCGF, T-cell growth factor; bp, base pair(s); kb, ki-
lobase(s).
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FIG. 1. Restriction map of human TCGF. TCGF X1O, X23, and X25 were isolated from a human DNA library in Charon 4A. The 2.1-kilobase
(kb) HindIII fragment (p15), 3.7-kb EcoRI fragment (p4l), and 3.6-kb HindIII fragment (p1l) were subcloned into pBR322 for DNA sequence
analysis. The locations of exons are indicated by black rectangles. E, EcoRI; H, HindIII; C, Cla I; S, Stu I; X, Xba I. The sequence is
represented from 5' to 3' going left to right.
DNA Sequence Analysis. DNA nucleotide sequences were
determined by the dideoxynucleotide termination method of
Sanger et al. (15) after subcloning restriction endonuclease
fragments into M13-mp8, mp9, mplO, and mpll phage vec-
tors. Sequences were analyzed and compared on an IBM
system 370 computer using the program described by Queen
and Korn (16).
mRNA Sequence Analysis and Identification of the Tran-
scription Initiation Site. A 5' 32P-end-labeled 31-base-pair
(bp) fragment from the TCGF cDNA beginning just after the
translation initiation codon and extending 3' was isolated by
cleavage of the cDNA with Dde I and Rsa I. This fragment
was used as a primer for mRNA sequence analysis following
the procedure of Bina-Stein et al. (17).
Materials. Human spleen, placental, and peripheral blood
lymphocyte genomic libraries were graciously provided by
P. Leder, T. Maniatis, and E. Benz, respectively. DNA
polymerase and DNase I were from Boehringer Mannheim;
restriction endonucleases were from Bethesda Research
Laboratories, New England BioLabs and Boehringer Mann-
heim; T4 DNA ligase, M13 phage vectors, T4-polynucleotide
kinase, and unlabeled deoxynucleotide triphosphates and di-
deoxynucleotide triphosphates were from P-L Biochemicals;
and [y- and a-32P]deoxynucleotide triphosphates were from
Amersham.
RESULTS AND DISCUSSION
Isolation and Sequence of cDNA Clones for TCGF. Of
>6000 cDNA clones tested for hybridization to the synthetic
oligonucleotide probe based on the published TCGF cDNA
sequence only 2 positives were detected. Neither of these
clones, which were 420 and 450 bp long, contained the com-
plete cDNA sequence. Nucleic acid sequence analysis
showed them both to contain the 5' portion of the message
with sequence identical to that reported by Taniguchi et al.
(6). The 420-bp clone started at the same place as the clone
reported by Taniguchi and extended to position 420 of that
clone. The 450-bp clone contained a few more residues 5' to
the 420-bp clone and extended farther 3'. The fact that both
of these clones contained the 5' end rather than 3' portion of
the cDNA, is likely due to selection of this region, because
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FIG. 2. Sequence analysis strategy for the human TCGF gene. The locations of the exons are indicated by black rectangles. Symbols for the
endonuclease restriction sites are the same as for Fig. 1. The introns are labeled A, B, and C. Arrows indicate the direction and length of the
clones used for sequence analysis.
the synthetic probe we used was directed toward the 5' end
of the message. Rescreening of the 6000 clones with these
partial cDNAs did not produce any other positive clones.
Isolation and Characterization of Genomic Clones. Approx-
imately 106 plaques from three different human genomic li-
braries in bacteriophage Charon 4A were screened for TCGF
using the cDNA probe. We were unsuccessful in isolating
the gene from two of these libraries (spleen and placental).
However, three overlapping clones containing the entire
TCGF gene and 5'- and 3'-flanking regions were isolated
from the peripheral blood lymphocyte library (Fig. 1). These
are designated X23, X10, and X25. Digestion of these clones
with restriction endonucleases and hybridization with a
labeled cDNA probe showed the gene to be contained within
two contiguous EcoRI fragments of -3700 bp each. Two
HindIII sites were shown to occur in one of these, while the
other contained a single HindIII site. These sites were used
to subclone the regions containing TCGF into pBR322, gen-
erating the three overlapping subclones p15, p41, and p1l.
Further analysis of these subclones with a variety of restric-
tion endonucleases and their known sites of cleavage in the
cDNA allowed the proper orientation of the two EcoRI frag-
ments and the construction of the map of the gene shown in
Fig. 1.
Sequence and Structure of the Isolated TCGF Gene. A com-
bination of directed and nondirected strategies was used to
determine the sequence of the TCGF gene (Fig. 2). The en-
tire sequence is shown in Fig. 3. The gene is 5040 bp long.
The sequence includes 292 nucleotides upstream from the
translation initiation site and extends 297 bp downstream
from the. polyadenylylation signal. Consistent with other
genes, a promoter sequence T-A-T-A-A-A occurs 77 bp up-
stream from the translation initiation site. A CAT homology
region, also implicated in the regulation of other genes, oc-
curs 104 nucleotides upstream from the translation initiation
site. To determine the site at which transcription is initiated,
we analyzed the sequence ofTCGF mRNA by extension of a
31-bp primer using reverse transcriptase. The primer, com-
plementary to the beginning of the coding region just after
the translation initiation site, was annealed to total Jurkat
poly(A) RNA, and extended by incorporation of deoxy- and
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10 20 30 40 50 60 70 80 90 100 110
CGAATTCCCC TATCACCTAA GTGTGGGCTA ATGTAACAAA GAGGGATTTC ACCTACATCC ATTCAGTCAG TCTTTGGGGG TTTAAAGAAA TTCCAAAGAG TCATCAGMG
120 130 140 150 160 170 180 190 200 210
AGGAAAAATG AAGGTAATGT TTTTTCAGAC TGGTAAAGTC TTTGAAAATA TGTGTAATAT GTAAAACATT TTGACACCCC CATAATATTT TTCCAGAATT
220 230 240 250 260 270 280 290 307
AACAG AT TGCATCTC TTGTTCAA(G GTTCCCTATC ACTCTTTAAT CACTACTCAC AGTAACCTCA ACTCCTGCCA CA ATG TAC AGG ATG CM CTC
MET Tyr Arg Met Gln Leu
322 337 352 367 382 397
CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACA MC AGT GCA CCT ACT TCA AGT TCT ACA AAG AAA ACA CAG CTA CAA CTG GAG
Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gin Leu Glu
412 427 449 459 469 479 489 499
CAT TTA CTG CTG GAT TTA CAG ATG ATT TTG AAT GGA ATT MT GTMGTATAT TTCCTTTCTT ACTAAAATTA TTACATTTAG TMTCTAGCT GGAGATCATT
His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn
509 519 529 544 559 574 589
TCTTAATAAC AATGCATTAT ACTTTCTTAG MT TAC AAG MT CCC AM CTC ACC AGG ATG CTC ACA TTT AAG TTT TAC ATG CCC MG AAG
Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys
599 609 619 629 639 649 659 669 679 689 699
GTAAGTACAA TATTTTATGT TCAATTTCTG TTTTAATAAA ATTCAAAGTA ATATGAAAAT TTGCACAGAT GGGACTMTA GCAGCTCATC TGAGGTAAAG AGTMCTTTA
709 719 729 739 749 759 7 69 779 789 799 809
ATTTGTTTTT TTGAAAACCC MGTTTGATA ATGMGCCTC TATTAAAACA GTTTTACCTA TATTTTTMT ATATATTTGT GTGTTGGTGG GGGTGGGAGA AAACATAAAA
819 829 839 849 859 869 879 889 899 909 919
ATAATATTCT CTCACTTTAT CGATAAGACA ATTCTAAACA AAAATGTTCA TTTATGGTTT CATTTAAAAA TGTAAAACTC TAAAATATTT GATTATGTCA TTTTAGTATG
929 939 949 959 969 979 989 999 1009 1019 1029
TAAMTACCA AAATCTATTT CCAAGGAGCC CACTTTTAAA AATCTTTTCT TGTTTTAGGA MGGTTTCTA AGTGAGAGGC AGCATACAC TAATAGCACA GAGTCTGGGG
1039 1049 1059 1069 1079 1089 1099 1109 1119 1129 1139
CCAGATATCT GMGTGAAAT CTCAGCTCTG CCATGTCCTA GCTTTCATGA TCTTTGGCAA ATTACCTACT CTGTTTGTGA TTCAGTTTCA TGTCTACTTA AATGAATMC
1149 1159 1169 1179 1189 1199 1209 1219 1229 1239 1249
TGTATATACT TAATATGGCT TTGTGAGMT TAGTMGTM ATGTAAAGCA CTCAGAACCG TGTCTGGCAT AAGGTAAATA CCATACAAGC ATTAGCTATT ATTAGTAGTA
1259 1269 1279 1289 1299 1309 1319 1329 1339 1349 1359
TTAAAGATAA MTTTTCACT GAGAAATACA AAGTAAAATT TTGGACTTTA TCTTTTTACC AATAGAACTT GAGATTTATA ATGCTATATG ACTTATTTTC CMGATTAAA
1369 1379 1389 1399 1409 1419 1429 1439 1449 1459 1469
AGCTTCATTA GGTTGTTTTT GGATTCAGAT AGAGCATAAG CATAATCATC CMGCTCCTA GGCTACATTA GGTGTGTAAA GCTACCTAGT AGCTGTGCCA GTTMGAGAG
1479 1489 1499 1509 1519 1529 1539 1549 1559 1569 1579
AATGAACAAA ATCTGGTGCC AGAAAGAGCT TGTGCCAGGG TGAATCCAAG CCCAGAAAAT AATAGGATTT AAGGGGACAC AGATGCAATC CCATTGACTC AAATTCTATT
1589 1599 1609 1619 1629 1639 1649 1659 1669 1679 1689
AATTCAAGAG AAATCTGCTT CTAACTACCC TTCTGAAAGA TGTAAAGGAG ACAGCTTACA GATGTTACTC TAGTTTAATC AGAGCCACAT MTGCAACTC CAGCMCATA
1699 1709 1719 1729 1739 1749 1759 1769 1779 1789 1799
AAGATACTAG ATGCTGTTTT CTGAAGAAAA TTTCTCCACA TTGTTCATGC CAAAAACTTA AACCCGAATT TGTAGAATTT GTAGTGGTGA ATTGAAAGCG CAATAGATGG
1809 1819 1829 i839 1849 1859 1869 1879 1889 1899 1909
ACATATCAGG GGATTGGTAT TGTCTTGACC TACCTTTCCC ACTAAAGAGT GTTAGAAAGA TGAGATTATG TGCATAATTT AGGGGTGGTA GAATTCATGG AAATCTAAGT
1919 1929 1939 1949 1959 1969 1979 1989 1999 2009 2019
TTGAAACCAA AAGTAATGAT AAACTCTATT CATTTGTTCA TTTAACCCTC ATTGCACATT TACAAAAGAT TTTAGAAACT AATAAAAATA TTTGATTCCA AGGATGCTAT
2029 2039 2049 2059 2069 2079 2089 2099 2109 2119 2129
GTTAATGCTA TAATGAGAAA GAAATGAAAT CTAATTCTGG CTCTACCTAC TTATGTGGTC AAATTCTGAG ATTTAGTGTG CTTATTTATA MGTGGAGAT GATACTTCAC
2139 2149 2159 2169 2179 2189 2199 2209 2219 2229 2239
TGCCTACTTC AAAAGATGAC TGTGAGAAGT AAATGGGCCT ATTTTGGAGA AAATTCTTTT AAATTGTAAT ATACCATAGA AATATGAAAT ATTATATATA ATATAGMTC
2249 2259 2269 2279 2289 2299 2309 2319 2329 2339 2349
AAGAGGCCTG TCCAAAAGTC CTCCCAAAGT ATTATAATCT TTTATTTCAC TGGGACAAAC ATTTTTAAAA TGCATCTTAA TGTAGTGATT GTAGAAAAGT AAAAATTTM
2359 2369 2379 2389 2399 2409 2419 2429 2439 2449 2459
GACATATTTA AAAATGTGTC TTGCTCAAGG CTATATTGAG AGCCACTACT ACATGATTAT TGTTACCTAG TGTAAAATGT TGGGATTGTG ATAGATGGCA TCCMGAGTT
2469 2479 2489 2499 2509 2519 2529 2539 2549 2559 2569
CCTTCTCTCT CMCATTCTG TGATTCTTAA CTCTTAGACT ATCAAATATT ATAATCATAG AATGTGATTT TTATGCCTTC CACATTCTM TCTCATCTGG TTCTAATGAT
2579 2589 2599 2609 2619 2629 2639 2649 2659 2669 2679
TTTCTATGCA GATTGGAAAA GTMTCAGCC TACATCTGTA ATAGGCATTT AGATGCAGAA AGTCTAACAT TTTGCAAAGC CAAATTMGC TAAAACCAGT GAGTCAACTA
2689 2699 2709 2719 2729 2739 2749 2759 27 69 2779 2789
TCACTTAACG CTAGTCATAG GTACTTGAGC CCTAGTTTTT CCAGTTTTAT AATGTAAACT CTACTGGTCC ATCTTTACAG TGACATTGAG AACAGAGAGA ATGGTAAAAA
2799 2809 2819 2829 2839 2849 2859 2869 2879 2896
CTACATACTG CTACTCCAAA TAAAATAAAT TGGAAATTAA TTTCTGATTC TGACCTCTAT GTAAACTGAG CTGATGATAA TTATTATTCT AG GCC ACA GAA CTG AAA
Ala Thr Glu Leu Lys
(Fig. 3 continues on the next page.)
Biochemistry: Holbrook et al. Proc. Natl. Acad Sci USA 81 (1984) 1637
2911 2926 2941 295 6 2971 298 6
CAT CTT CAG TGT CTA GAA GAA GAA CTC AAA CCT CTG GAG GAA GTG CTA AAT TTA GCT CAA AGC AAA AAC TTT CAC TTA AGA CCC AGG GAC
His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp
3001 3016 3035 3045 3055 3065 3075 3085
TTA ATC AGC AAT ATC AAC GTA ATA GTT CTG GAA CTA AAG GTMGGCATT ACTTTATTTG CTCTCCTGGA AATAAAAAAA AAAAAGTAGG GGGAAAAGTA
Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys
3095 3105 3115 3125 3135 3145 3155 3165 3175 3185 3195
CCACATTTTA AAGTGACATA ACATTTTTGG TATTTGTAAA GTACCCATGC ATGTAATTAG CCTACATTTT AAGTACACTG TGAACATGAA TCATTTCTAA TGTTAAATGA
3205 3215 3225 3235 3245 3255 3265 3275 3285 3295 3305
TTAACTGGGG AGTATAAGCT ACTGAGTTTG CACCTACCAT CTACTAATGG ACAAGCCTCA TCCCAAACTC CATCACCTTT CATATTAACA CAAAACTGGG AGTGAGAGAG
3315 3325 3335 3345 3355 3365 3375 3385 3395 3405 3415
AAGTGACTGA GTTGAGTTTC ACAGAAACGC AGGCAAGATT TTATTATATA TTTTTCMGT TCCTTCACAG ATCATTTACT GGAATAGCCA ATACTGAGTT ACCTGAAAGG
3425 3435 3445 3455 3465 3475 3485 3495 3505 3515 3525
CTTTTCAAAT GGTGTTTCCT TATCATTTGA TGGAAGGACT ACCCATAAGA GATTTGTCTT AAAAAAAAAA ACTGGAGCCA TTAAAATGGC CAGTGGACTA AACAAACAAC
3535 3545 3555 3565 3575 3585 3595 3605 3615 3625 3635
AATCTTTTTA GAGGCMTCC CACTTTCAGA ATCTTAAGTA TTTTTAAATG CACAGGAAGC ATAAAATATG CAAGGGACTC AGGTGATGTA AAAGAGATTC ACTTTTGTCT
3645 3655 3665 3675 3685 3695 3705 3715 3725 3735 3745
TTTTATATCC CGTCTCCTAA GGTATAAAAT TCATGAGTTA ATAGGTATCC TAAATAAGCA GCATAAGTAT AGTAGTAAAA GACATTCCTA AAAGTAACTC CAGTTGTGTC
3755 3765 3775 3785 3795 3805 3815 3825 3835 3845 3855
CAAATGAATC ACTTATTAGT GGACTGTTTC AGTTGAATTA AAAAAATACA TTGAGATCAA TGTCATCTAG ACATTGACAG ATTCAGTTCC TTATCTATGG CAAGAGTTTT
38 65 3875 3885 3895 3905 3915 3925 3935 3945 3955 39 65
ACTCTAAAAT AATTAACATC AGAAAACTCA TTCTTAACTC TTGATACAAA TTTAAGACAA AACCATGCAA AAATCTGAAA ACTGTGTTTC AAAAGCCAAA CACTTTTTAA
3975 3985 3955 4005 4015 4025 4035 4045 4055 4065 4075
AATAAAAAAA TCCCAAGATA TGACAATATT TAAACAATTA TGCTTAAGAG GATACAGAAC ACTGCAACAG TTTTTTAAAA GAGAATACTT ATTTAAAGGG AACACTCTAT
4085 4095 4105 4115 4125 4135 4145 4155 4165 4175 4185
CTCACCTGCT TTTGTTCCCA GGGTAGGAAT CACTTCAAAT TTGAAAAGCT CTCTTTTAAA TCTCACTATA TATCAAAATA GTTGCCTCCT TAGCTTATCA ACTAGAGGAA
4195 4205 4215 4225 4235 4245 4255 4265 4275 4285 4295
GCGTTTAAAT AGCTCCTTTC AGCAGAGAAG CCTAATTTCT AAAAAGCCAG TCCACAGAAC AAAATTTCTA ATGTTTAAAG CTTTTAAAAG TTGGCAAATT CACCTGCATT
4305 4315 4325 4335 4345 4355 4365 4375 4385 4395 4405
GATACTATGA TGGGGTAGGG ATAGGTGTAA GTATTTATGA AGATGTTCAT TCACACAAAT TTACCCAAAC AGGAAGCATG TCCTACCTAG CTTACTCTAG TGTAGCTCGT
4415 4425 4435 4445 4455 4465 4475 4485 4495 4505 4515
TTCGTCTTTG GGGAAAATAT AAGGAGATTC ACTTAAGTAG AAAAATAGGA GACTCTAATC AAGATTTAGA AAAGAAGAAA GTATMTGTG CATATCMTT CATACATTTA
4525 4535 4545 4555 4565 4575 4585 4595 4605 4615 4625
ACTTACACAA ATATAGGTGT ACATTCAGAG GAAAAGCGAT CMGTTTATT TCACATCCAG CATTTAATAT TTGTCTAGAT CTATTTTTAT TTAAATCTTT ATTTGCACCC
4635 4645 4655 4665 4675 4685 4695 4705 4715 4725 4735
MTTTAGGGA AAAAATTTTT GTGTTCATTG ACTGAATTAA CAAATGAGGA AAATCTCAGC TTCTGTGTTA CTATCATTTG GTATCATMC AAAATACGCA ATTTTGGCAT
4745 4755 4765 4775 4785 4795 4805 4815 4825 4835 4845
TCATTTTGAT CATTTCAAGA AAATGTGAAT AATTAATATG TTTGGTAAGC TTGAAAATM AGGCAACAGG CCTATAAGAC TTCAATTGGG MTAACTGTA TATMGGTM
4855 4865 4875 4885 4901 4916 4931.
ACTACTCTGT ACTTTAAAAA ATTAACATTT TTCTTTTATA G GGA TCT GAA ACA ACA TTC ATG TGT GAA TAT GCT GAT GAG ACA GCA ACC ATT GTA GAA
Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu
4946 49 61 4976 4991 5004 5014 5024 5034
TTT CTG AAC AGA TGG ATT ACC TTT TGT CAA AGC ATC ATC TCA ACA CTG ACT [TGAAMTTAA GTGCTTCCCA CTTAAAACAT ATCAGGCCTT
Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr Leu Thr
5044 5054 5064 5074 5084 5094 5104 5114 5124 5134 5144
CTATTTATTT AAATATTTAA ATTTTATATT TATTGTTGM TGTATGGTTT GCTACCTATT GTAACTATTA TTCTTMTCT TAAAACTATA MTATGGATC TTTTATGATT
5154 5164 5174 5184 5194 5204 5214 5224 5234 5244 5254
CTTTTTGTAA GCCCTAGGGG CTCTAAAATG GTTTCACTTA TTTATCCCAA AATATTTATT ATTATGTTGA ATGTTAAATA TAGTATCTAT GTAGATTGGT TAGTAAAACT
5264 5274 5284 5294 5304 5314 5324 5334 5344 5354 5364
ATTIIAATAAAI TTTGATAAAT ATAAACAAGC CTGGATATTT GTTATTTTGG AAACAGCACA GAGTAAGCAT TTAAATATTT CTTAGTTACT TGTGTGAACT GTAGGATGGT
5374 5384 5394 5404 5414 5424 5434 5444 5454 5464 5474
TAAAATGCTT ACAAAAGTCA CTCTTTCTCT GAAGAAATAT GTAGAACAGA GATGTAGACT TCTCAAAAGC CCTTGCTTTG TCCTTTCAAG GGCTGATCAG ACCCTTAGTT
5484 5494 5504 5514 5524 5534 5544 5554
CTGGCATCTC TTAGCAGATT ATATTTTCCT TCTTCTTAAA ATGCCAAACA CAAACACTCT TGAAACTCTT CATAGATTTG GTGTGGC
FIG. 3. DNA sequence of the human TCGF gene. The amino acid sequences encoded by exons of TCGF are shown below the DNA
sequences. The 3'- and 5'-untranslated regions are underlined. The T-A-T-A-A-A box, putative transcription initiation site, translation initiation
codon, termination codon, and polyadenylylation signal are enclosed in rectangles.
transcription starts 53 nucleotides from the translation initia- Comparison of the human genomic TCGF sequence with
tion site. Consistent with these findings, an A (indicated in that of the cDNA revealed that the gene is divided into four
Fig. 2), which occurs at most transcription initiation sites, is exons separated by intervening sequences. Exon 1 contains
present at this position. the 5 -nontranslated region and codes for the first 49 amino
1638 Biochemistry: Holbrook et al.
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FIG. 4. Southern blot analysis of the TCGF gene in cellular
DNA. Cellular DNA (10 Ag) prepared from normal peripheral mono-
nuclear cells of an individual and digested with EcoRI (R1), HindIII,
and Xba I was fractionated on an agarose gel, transferred to nitrocel-
lulose paper, and hybridized with a 32P-labeled TCGF cDNA probe.
acids of TCGF, 20 of which constitute the putative signal
polypeptide (6). An intervening sequence of 91 bp separates
this exon from exon 2, 60 bp long, which codes for the next
20 amino acids. The second and third exons are separated by
a long intervening sequence of 2292 bp. Exon 3 (144 bp),
which codes for the next 48 amino acids, is again followed by
a long intervening sequence 1364 bp long. The fourth and
final exon codes for the remaining 36 amino acid residues
followed by the termination codon TGA. The polyadenylyla-
tion signal occurs 261 nucleotides after the termination co-
don. The consensus sequences, A-G and G-T, occur at the 5'
and 3' exon-intron junctions, respectively, in all cases. A
single difference in the nucleotide sequence of the gene cod-
ing for TCGF and that reported for the cDNA by Taniguchi
et al. (6) was noted. Those workers reported an A at position
503 of their cDNA clone. This corresponds to position 4879
of our genomic sequence, where we find a G residue. Either
nucleotide results in a codon for leucine. Computer analysis
of the sequence revealed no segments of repetitive sequence
within the introns.
It is worth noting that several regions of homology with a
number of different potential enhancer core elements are
present in the second intron. These include position 678-691
homologous with the Mo-MSV core sequence (18), position
1430-1440 homologous with the SV40 core element (19), po-
sition 1514-1527 homologous with the SNV element (20),
and position 1702-1715 homologous with the mouse Ig
heavy-chain core element (21).
The TCGF Gene in Normal and Malignant Cells. The orga-
nization of TCGF in cellular DNAs prepared from peripheral
blood lymphocytes of 6 formal individuals, lymphoma tissue
from 15 patient specimens, epithelial thymoma tissue from 1
patient specimen, and 7 cell lines was compared by Southern
blot analysis after digestion of the DNA with the restriction
endonucleases EcoRI, HindIII, and Xba I. The lymphoma
tissues included 14 B- and 1 T-cell malignancies. The cell
lines included the following: 4 MLA (gibbon ape T cell) sub-
clones, 2 Jurkat (human T cell) subclones, and 1 HUT (hu-
man T-celi leukemia virus infected T-cell line) subclone. The
findings were similar in all cases examined and a repre-
sentative Southern blot is shown in Fig. 4. The restriction
fragments hybridizing to the cDNA clone are precisely those
predicted from the map in Fig. 1. The 900-bp Xba I fragment
hybridizes weakly, because it has only 124 nucleotides ho-
mologous to the cDNA. The 4000-bp Xba I fragment and the
5000-bp HindIII fragment (Fig. 2) do not hybridize, because
our cDNA has only 16 nucleotides from the fourth exon and
therefore would not be expected to form a stable hybrid to
this exon under the highly stringent conditions used. Since
all of the restriction fragments hybridizing to the cDNA can
be explained by the locus shown in Fig. 1, it is likely there is
only a single copy of the human TCGF gene and in the limit-
ed number of malignant cells examined, the gene is not rear-
ranged. This latter point must be qualified by the recognition
that we have not examined a large number of malignant hu-
man T cells and that a more extensive survey is essential.
Although it is clear that TCGF plays a key role in mediat-
ing the T-cell proliferation that results from activation of T
cells by mitogen, nothing is known of the molecular mecha-
nisms associated with these processes. With the organiza-
tion and sequence of the TCGF gene established, we are now
in a position to study directly at the genomic level how mito-
gens regulate TCGF. Such studies should lead to an in-
creased understanding of T-cell differentiation.
Note Added in Proof. Fujita et al. (22) also recently reported the
complete nucleotide sequence for human TCGF. It is valuable to
compare these two sequences obtained by different sequencing pro-
cedures as there are a number of small discrepancies, particularly
within the third intron. There are no discrepancies in the coding or
enhancer-like sequences.
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